“…Some genetic and immunological mechanisms have been associated with the resistant phenotype as follows: (i) genetic polymorphisms in the required co-receptors for viral entry, such as CCR5 or CCR2 ( 5 , 6 ); (ii) increased production of the co-receptor ligands MIP-1α/β, RANTES or SDF-1; (iii) the presence of antibodies blocking viral co-receptors ( 7 ); (iv) the expression of different microRNAs induced by the viral exposure ( 8 , 9 ) that may modulate the innate immune system or interfere directly with viral mRNAs blocking the infection ( 10 ); (v) induction of spontaneous apoptosis of target cells ( 6 , 11 ); (vi) production of soluble factors with antiviral activity, such as TRIM5α, APOBEC-3G, SAMHD-1, serpina1, elafin, Human neutrophil peptide, beta-defensins, and LL-37 ( 12 – 14 ), other proteins implicated in host defense and bacterial binding, such as bPRP2, Histatin-3, Lysozyme C, and SLPI ( 15 ), and the presence of non-cationic proteins in genital secretions with HIV-1 neutralizing activity ( 16 ); (vii) high activity of natural killer cells ( 17 , 18 ) and dendritic cells (DC) ( 19 ); (viii) high levels of neutralizing IgA antibodies ( 18 , 20 ), which are even associated with protection in vaccine clinical trials, as they could prevent HIV mucosal transcytosis ( 21 ); (ix) expression of the alleles HLA-B57 and -B27 that present immunodominant peptides ( 6 ); and (x) effective and polyfunctional profile of HIV-specific CD4 + and CD8 + T cell responses ( 22 , 23 ).…”